POAI Valuation

Predictive Oncology Inc

Add to Watchlist

Advanced Chart

0.790

+0.009(1.152%)1D

Overview
Forecast
Valuation
Earnings

POAI Relative Valuation

POAI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, POAI is overvalued; if below, it's undervalued.

Historical Valuation

Predictive Oncology Inc (POAI) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.69 is considered Undervalued compared with the five-year average of -3.23. The fair price of Predictive Oncology Inc (POAI) is between 130.39 to 131.16 according to relative valuation methord. Compared to the current price of 0.79 USD , Predictive Oncology Inc is Undervalued By 99.39%.

Relative Value

Fair Zone

130.39-131.16

Current Price：0.79

99.39%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

-48.14

P/B

Median3y

-3.70

Median5y

-1.24

-123.82

FCF Yield

Median3y

-128.33

Median5y

-92.28

Competitors Valuation Multiple

The average P/S ratio for POAI's competitors is 493.39, providing a benchmark for relative valuation. Predictive Oncology Inc Corp (POAI) exhibits a P/S ratio of 0.69, which is -99.86% above the industry average. Given its robust revenue growth of 2170.69%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

POAI.O

Predictive Oncology Inc

0.69

Average P/S: 493.39

2170.69%